Company intelligence / Profile preview
Pars Isotope
Tehran, Tehran Province, Iranparsisotope.com ↗
- Ownership
- Private
- Employees
- ~330
- Development stage
- Other
01
Overview
Pars Isotope supplies commercial radiopharmaceuticals widely used in nuclear medicine across Iran and the region. The company has at least one peptide-conjugated radionuclide therapeutic targeting FAP in Phase 1 trials for metastatic gastrointestinal cancer. It also collaborates on a Phase 2 investigator-led study of technetium/lutetium-labeled PSMA agents for glioblastoma. No published pivotal efficacy results yet.
- Therapeutic areas
- NeurologyDermatologyGastroenterologyOncologyRheumatologyCardiovascular
- Modalities
- RadiopharmaceuticalPeptide conjugate radionuclide
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
03
Partnerships
Emerald Pro. Ltd. (Egypt)Megaline Sourcing (Pakistan)Soliri S.A.R.L. (Lebanon)Vishat Diagnostics Pvt. Ltd. (India)
Beyond the preview
Go deeper on Pars Isotope.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Pars Isotope.